Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- darifenacin
- nitrofurantoin
Interactions between your drugs
nitrofurantoin darifenacin
Applies to: nitrofurantoin, darifenacin
Anticholinergic agents may increase the absorption and oral bioavailability of nitrofurantoin. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents. In six healthy volunteers, pretreatment with propantheline 45 minutes before a single 100 mg dose of nitrofurantoin significantly increased the oral bioavailability of nitrofurantoin as indicated by a 68% increase in urinary recovery. In another study, atropine 500 mcg given subcutaneously one-half hour before a single 100 mg dose of nitrofurantoin delayed the absorption and urinary excretion of nitrofurantoin but did not affect its overall bioavailability in ten healthy volunteers. The clinical significance of these changes is unknown.
References (2)
- Mannisto P (1978) "The effect of crystal size, gastric content and emptying rate on the absorption of nitrofurantoin in healthy human volunteers." Int J Clin Pharmacol Biopharm, 16, p. 223-8
- Jaffe JM (1975) "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci, 64, p. 1729-30
Drug and food interactions
darifenacin food
Applies to: darifenacin
The consumption of grapefruit juice may be associated with increased plasma concentrations of darifenacin. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The clinical significance is unknown.
References (1)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Gemtesa
Gemtesa (vibegron) is used to treat overactive bladder symptoms (OAB) in adults or men taking ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
Estrace
Estrace (estradiol) is used to treat symptoms of menopause such as hot flashes and vaginal dryness ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Estradiol Patch
Estradiol Patch is used for atrophic urethritis, atrophic vaginitis, breast cancer, palliative ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.